CCR5 Overview
Molecule Name
C-C chemokine receptor type 5
Synonyms
CCR5,CMKBR5,CD195,CC-CKR-5,CHEMR13
Drug Development Progress
Drugs in Clinical Trials13
Approved Drugs1
Highest Development StageApproved
Target Synonym
CCR-5，Chemokine (C-C Motif) Receptor 5 (Gene/Pseudogene)，C-C Motif Chemokine Receptor 5 A159A，Chemokine Recptor CCR5 Delta32，C-C Chemokine Receptor Type 5，Chemokine Receptor CCR5，CD195 Antigen，C-C CKR-5，CCCKR5，IDDM22，CKR-5，CKR5，Receptors， CCR5，C-C Motif Chemokine Receptor 5，CD195，CHEMR13，CCR5，HIV-1 fusion coreceptor，C-C Motif Chemokine Receptor 5 (Gene/Pseudogene)，Chemokine (C-C Motif) Receptor 5，CC-CKR-5，CMKBR5
Background
Receptor for a number of inflammatory CC-chemokines including CCL3/MIP-1-alpha, CCL4/MIP-1-beta and RANTES and subsequently transduces a signal by increasing the intracellular calcium ion level. May play a role in the control of granulocytic lineage proliferation or differentiation.5 Publications (Microbial infection) Acts as a coreceptor (CD4 being the primary receptor) of human immunodeficiency virus-1/HIV-1.
CCR5 Product List
You Have Viewed 0 Of 0 Results
Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Cenicriviroc mesylate | CCR5/CCR2 antagonist; TBR-652; CVC; TAK-652 | Phase 3 Clinical | Takeda Pharmaceutical Co Ltd, Tobira Therapeutics Inc | AIDS Dementia Complex; Cholangitis, Sclerosing; Cognition Disorders; Coronavirus Disease 2019 (COVID-19); Diabetes Mellitus, Type 2; Hepatic Insufficiency; HIV Infections; Liver Cirrhosis; Metabolic Dysfunction-Associated Steatotic Liver Disease; Obesity; Prediabetic State | Details |
| SB-728-T | SB-728mR-T; SB-728-T | Phase 2 Clinical | Sangamo Biosciences | HIV Infections | Details |
| Vicriviroc | SCH-D; MK-4176; SCH-417; Sch-417690 | Phase 2 Clinical | Merck & Co Inc | Acquired Immunodeficiency Syndrome; Colorectal Neoplasms; HIV Infections | Details |
| Leronlimab | PA-14; PRO-140; HuPRO-140 | Phase 2 Clinical | Progenics Pharmaceuticals Inc | Colorectal Neoplasms; Coronavirus Disease 2019 (COVID-19); Graft vs Host Disease; HIV Infections; Metabolic Dysfunction-Associated Steatotic Liver Disease; Rectal Neoplasms; Solid tumours; Triple Negative Breast Neoplasms | Details |
| BMS-813160 | BMS-813160 | Phase 2 Clinical | Bristol-Myers Squibb Company | Adenocarcinoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Colorectal Neoplasms; Diabetic Nephropathies; Hyperplasia; Pancreatic Neoplasms | Details |
| RAP-103 | RAP-160; RAP-701; RAP-164; RAP-310; RAP-163; RAP-103 | Phase 2 Clinical | Rapid Pharmaceuticals | Alzheimer Disease; Hepatitis B; Neuralgia; Ovarian Neoplasms; Prostatic Neoplasms; Psoriasis | Details |
| Cenicriviroc mesylate/Tropifexor | LJC-242 | Phase 2 Clinical | Novartis Pharma Ag | Metabolic Dysfunction-Associated Steatotic Liver Disease | Details |
| AGT 103-T | AGT 103-T | Phase 1 Clinical | American Gene Technologies International Inc | HIV Infections | Details |
| Thioraviroc | Phase 1 Clinical | Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences | Amyotrophic Lateral Sclerosis; HIV Infections; Multiple Sclerosis | Details | |
| BMS-687681 | BMS-687681 | Phase 1 Clinical | Bristol-Myers Squibb Company | Neoplasms | Details |
| SB-728-HSC | SB-728-HSC; SB-728-HSPC; SB-728mR-HSPC | Phase 1 Clinical | Sangamo Biosciences | HIV Infections | Details |
| vMIP (Guangzhou Hongrun Biotech) | Phase 1 Clinical | Guangzhou Hongrun Biotechnology Co Ltd | Pneumonia | Details | |
| LF-0376 | LF-0376 | Phase 1 Clinical | Wuxi Hillhouse biomedicine Technology Co Ltd | Colorectal Neoplasms; Liver Neoplasms; Lymphoma; Lymphoma, Large B-Cell, Diffuse; Pancreatic Neoplasms; Solid tumours | Details |
Marketed Drug Information
| English Name | Research Code | Highest Development Stage | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Maraviroc | MVC; UK-427857 | Approved | Viiv Healthcare | Celsentri, Selzentry | United States | HIV Infections | Viiv Healthcare Co | 2007-08-06 | Acquired Immunodeficiency Syndrome; Acute Lung Injury; AIDS Dementia Complex; Arthritis, Rheumatoid; Cardiovascular Diseases; Cognition Disorders; Coronavirus Disease 2019 (COVID-19); HIV Infections; Hypertriglyceridemia; Inflammation; Ischemic Stroke; Kidney Diseases; Primary Graft Dysfunction; Rejection of lung transplantation; Sarcoma, Kaposi; Stroke | Details |